Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.
Saved in:
| Title: | Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial. |
|---|---|
| Authors: | Tate M; Department of Respiratory Medicine, Queen Elizabeth University Hospital, Glasgow, United Kingdom.; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Illingworth CJR; MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom., MacGregor G; Department of Respiratory Medicine, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Cunningham L; Cancer Research UK-Glasgow Clinical Trials Unit, Glasgow, United Kingdom., Divers L; Cancer Research UK-Glasgow Clinical Trials Unit, Glasgow, United Kingdom., McCartney E; Cancer Research UK-Glasgow Clinical Trials Unit, Glasgow, United Kingdom., Paterson L; Cancer Research UK-Glasgow Clinical Trials Unit, Glasgow, United Kingdom., Kelly C; Cancer Research UK-Glasgow Clinical Trials Unit, Glasgow, United Kingdom., Shaw A; Cancer Research UK-Glasgow Clinical Trials Unit, Glasgow, United Kingdom., Perkins JS; Glasgow Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Silva V; Glasgow Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Holland P; Glasgow Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Dalton C; Glasgow Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Carmichael S; Glasgow Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Douglas E; Glasgow Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Surtees P; Glasgow Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Scott JT; MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom., Berry C; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom., Vattipally S; MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom., Da Silva Filipe A; MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom., Tong L; MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom., Gunson R; West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, United Kingdom., McInnes IB; School of Infection and Immunity, University of Glasgow, Glasgow, United Kingdom., Jones R; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.; Cancer Research UK-Glasgow Clinical Trials Unit, Glasgow, United Kingdom., Thomson E; MRC University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.; School of Infection and Immunity, University of Glasgow, Glasgow, United Kingdom., Blyth KG; Department of Respiratory Medicine, Queen Elizabeth University Hospital, Glasgow, United Kingdom.; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.; Cancer Research UK Scotland Institute, Glasgow, United Kingdom. |
| Corporate Authors: | GETAFIX trial co-investigators |
| Source: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2025 Aug 06; Vol. 69 (8), pp. e0005425. Date of Electronic Publication: 2025 Jun 24. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
